SCHEMBL1747352

SCHEMBL1747352

COCOc1c(COc2ccc(CCC(=O)OC)cc2)sc2ccccc12

nearest known ligand 0.43

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
VDR P11473 2/20 0.41
ADRB2 P07550 1/20 0.40
ADRB1 P08588 1/20 0.40
FFAR1 O14842 8/20 0.40
FFAR4 Q5NUL3 2/20 0.40
AKR1B1 P15121 1/20 0.39
CASP3 P42574 1/20 0.39
CASP7 P55210 1/20 0.39
PPARD Q03181 1/20 0.39
CNR2 P34972 1/20 0.38
PPARG P37231 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745138 0.91 FFAR1 (0.52) FFAR1FFAR4AKR1B1
SCHEMBL1744944 0.86 FFAR1 (0.47) VDRFFAR1FFAR4AKR1B1PPARD
SCHEMBL1746798 0.85 VDR (0.46) VDRADRB2ADRB1FFAR1FFAR4
SCHEMBL1746635 0.84 MAPT (0.45) VDRADRB2ADRB1FFAR1FFAR4
SCHEMBL4633571 0.76 CXCR2 (0.55) FFAR1CASP3CASP7PPARG
SCHEMBL1746796 0.76 FFAR1 (0.59) FFAR1FFAR4AKR1B1
SCHEMBL1744783 0.75 FFAR1 (0.48) VDRADRB2ADRB1FFAR1FFAR4
SCHEMBL1745088 0.73 FFAR1 (0.58) FFAR1FFAR4AKR1B1PPARDPPARG
SCHEMBL4603385 0.73 CXCR2 (0.53) FFAR1CNR2PPARG
SCHEMBL1745247 0.73 FFAR1 (0.72) FFAR1FFAR4AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR VDR 117/4885ADRB2 316/4885ADRB1 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.